NUVBNuvation Bio Inc.

NYSE nuvationbio.com


$ 2.78 $ -0.14 (-4.81 %)    

Friday, 07-Jun-2024 15:59:40 EDT
QQQ $ 462.76 $ -0.41 (-0.09 %)
DIA $ 388.38 $ -0.84 (-0.22 %)
SPY $ 533.54 $ -0.65 (-0.12 %)
TLT $ 91.51 $ -1.71 (-1.83 %)
GLD $ 211.60 $ -7.83 (-3.57 %)
$ 2.77
$ 2.87
$ 0.00 x 0
$ 0.00 x 0
$ 2.72 - $ 2.87
$ 0.95 - $ 4.16
1,572,990
na
606.76M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-11-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-nuvation-bio-maintains-8-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.

 reported-saturday-nuvation-bio-revealed-findings-from-the-crucial-phase-2-trust-i-trial-of-their-experimental-ros1-inhibitor-taletrectinib-at-the-asco-2024

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of t...

 wedbush-reiterates-outperform-on-nuvation-bio-maintains-5-price-target

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.

 hc-wainwright--co-reiterates-buy-on-nuvation-bio-maintains-8-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.

 wedbush-reiterates-outperform-on-nuvation-bio-maintains-5-price-target

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.

 nuvation-bio-q1-2024-adj-eps-007-beats-010-estimate

Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by...

 rbc-capital-maintains-outperform-on-nuvation-bio-raises-price-target-to-5

RBC Capital analyst Kennen MacKay maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $4 t...

 profoundbio-discovers-the-joys-of-having-a-wealthy-owner

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...

 intel-xpeng-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday.

 hc-wainwright--co-maintains-buy-on-nuvation-bio-raises-price-target-to-8

HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from ...

 why-luxurban-hotels-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fo...

 cintas-reports-upbeat-earnings-joins-paysign-noah-holdings-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

 netflix-to-rally-over-15-here-are-10-top-analyst-forecasts-for-wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 why-mariadb-shares-are-trading-higher-by-around-100-here-are-20-stocks-moving-premarket

Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announce...

 jefferies-upgrades-nuvation-bio-to-buy-raises-price-target-to-10

Jefferies analyst Michael Yee upgrades Nuvation Bio (NYSE:NUVB) from Hold to Buy and raises the price target from $1.4 to $10.

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION